Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Iptacopan in Primary IgA Nephropathy
2024-511067-29-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Iptacopan with Placebo (2 arms). Primary endpoints: Primary Endpoint for Interim Analysis and Primary Endpoint for Final Analysis. Started Jan 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-511067-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511067-29-00.